Literature DB >> 34084276

Advances in innovative exosome-technology for real time monitoring of viable drugs in clinical translation, prognosis and treatment response.

Mujib Ullah, Nicole Pek Min Qian, Gustavo Yannarelli.   

Abstract

Entities:  

Keywords:  artificial intelligence; cancer; drug delivery; exosomes; extracellular vesicles

Year:  2021        PMID: 34084276      PMCID: PMC8169069          DOI: 10.18632/oncotarget.27927

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


× No keyword cloud information.

Innovative technologies and exosomes

In the field of medicine, technological discovery is a vital way to bridge knowledge gaps and equip us with the know-how to address biological challenges. Innovative technologies allow us to work faster and better understand complexities, especially pertaining to human health and disease [1-3]. Computer simulation and artificial intelligence play a significant role in the timely diagnosis and effective treatment of complex ailments such as cancer [2-5]. The inquisition towards developing and acquiring new technologies is quintessential in the journey towards improving the quality of patient care. The advent of advanced exosome purification methods has made it possible to tap on the unexplored potential of these tiny particles in clinically-precise diagnosis and treatment of a myriad of diseases [6-8]. More efforts are currently being funneled into research and development endeavors in order to increase the quality and reach of exosomes-based diagnostic and therapeutic applications in the near future. Exosomes are small nano-particles made by cells within our body [8-10]. They contain crucial information by way of proteins, metabolites, and nucleic acids, facilitating cell-cell communication cells [8-10]. Structurally, exosomes are surrounded by lipid bilayers, which provides a robust layer of protection to the biological contents stored within [10]. The abundance of adhesive and surface proteins found on the surface of exosomes readily interact with the cellular membrane of target cells, allowing exosomes to essentially be vehicles to deliver cargo such as drugs [10-12]. The innovative use of exosomes as drug delivery systems for small molecules, cytokines, and other biological components makes them an ideal choice for clinical use [13]. In addition, the recent COVID19 pandemic has opened up new opportunities for exosome technology to benefit humankind. In the realm of vaccine development, researchers are creating vaccines that consist of exosomes engineered to display SARS-CoV-2 proteins on their surface [14-16]. Also, since exosomes are known to be resistant to immune attack, lysis, and degradation [13, 16–18], they can be exploited for use as an early-stage diagnostic marker. Many conventional biomarkers that are often proteinaceous-in-nature are unprotected from biofluids which are home to degradative enzymes such as proteases [17, 19]. Exosomes, which are encapsulated within lipid bilayers, will be able to withstand said harsh conditions and are stable for a prolonged duration of time. Therefore, exosome-based biomarkers are attractive options for efficient diagnosis of diseases such as cancer. Other benefits that could give exosomes the edge over existing platforms are that they are less immunogenic, less cytotoxic, and due to sheer size, can easily cross biological barriers such as the blood–brain barrier (BBB) [19-21]. Innovations pertaining to the engineering of exosomes have progressively circumvented the limitations of naive exosomes (naturally-occurring exosomes produced by cells), which are known to have lower targeting capabilities, are more challenging to isolate, low drug loading capacities, bioavailability issues, low half-life in circulation, and low concentration of functional surface receptors [22-24]. Engineered exosomes are manipulated in a way that they can be loaded with maximum amounts of components such as drugs or miRNAs, and have higher specificity and delivery efficacies [13, 24, 25]. Additionally, engineered exosomes have other advantages over native exosomes, such as lower production cost, higher biocompatibility, and low undesirable effects such as cytotoxic effects [25, 26]. No doubt, the clinical application of exosomes can be enhanced by intelligent engineering methods for improving the delivery of drugs, genes, heat shock proteins, and functional bioactive molecules to target tissues [26-28]. They also have the capabilities to penetrate deeper within tissues with their surface ligands and receptors (Figure 1) [27, 28].
Figure 1

Schematic illustration showing the application of exosome technology in major clinical uses and in different scientific investigation.

Conclusions and Future Directions

New and emerging technologies play a significant role in permitting exosome detection and tracking, in vivo monitoring and analysis [29-31]. Magnetically-labeled particles and optical sensors offer great promise for in vivo monitoring, and detection of exosomes [31, 32]. Innovative technologies are also beneficial to improve exosome target specificity, which translates to higher sensitivity of patients to drug response, reduction in treatment cost, and greater disease outcome [31-33]. Artificial, digital, and optical technologies, when used in combination, have the potential to detect exosomes at the single-particle level or at very minimal concentrations, which have a high diagnostic value [33-36]. Collectively, exosome technology will revolutionize the field of diagnostics and treatment of human diseases (Figure 1). Nonetheless, further optimization of current methods and fine-tuning of technologies are necessary to push the field towards real clinical value [37, 38]. Exosomes technology has already been increasingly used in disease diagnosis and treatment; this encourages researchers to channel more efforts into overcoming limitations and challenges in the field [38, 39] such as issues related to the purification of exosomes from their parent source, eliminating contaminants, reducing the damage of exosomes from the harsh ultracentrifugation method (which spins the exosomes at ultra-speed and damages their membrane and enclosed therapeutic content) [39-42].
  37 in total

Review 1.  Exosomes: composition, biogenesis and function.

Authors:  Clotilde Théry; Laurence Zitvogel; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2002-08       Impact factor: 53.106

2.  Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo.

Authors:  Frederik J Verweij; Celine Revenu; Guillaume Arras; Florent Dingli; Damarys Loew; D Michiel Pegtel; Gautier Follain; Guillaume Allio; Jacky G Goetz; Pascale Zimmermann; Philippe Herbomel; Filippo Del Bene; Graça Raposo; Guillaume van Niel
Journal:  Dev Cell       Date:  2019-02-07       Impact factor: 12.270

Review 3.  Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications.

Authors:  Claudia Arenaccio; Chiara Chiozzini; Flavia Ferrantelli; Patrizia Leone; Eleonora Olivetta; Maurizio Federico
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

4.  Visualization of exosomes from mesenchymal stem cells in vivo by magnetic resonance imaging.

Authors:  Tianqi Liu; Yurong Zhu; Ruiting Zhao; Xinhua Wei; Xuegang Xin
Journal:  Magn Reson Imaging       Date:  2020-02-03       Impact factor: 2.546

Review 5.  Exosomes and Nanoengineering: A Match Made for Precision Therapeutics.

Authors:  Phuong H L Tran; Dongxi Xiang; Thao T D Tran; Wang Yin; Yumei Zhang; Lingxue Kong; Kuisheng Chen; Miaomiao Sun; Yong Li; Yingchun Hou; Yimin Zhu; Wei Duan
Journal:  Adv Mater       Date:  2019-09-18       Impact factor: 30.849

Review 6.  Novel nanosensing technologies for exosome detection and profiling.

Authors:  Hyungsoon Im; Kyungheon Lee; Ralph Weissleder; Hakho Lee; Cesar M Castro
Journal:  Lab Chip       Date:  2017-08-22       Impact factor: 6.799

Review 7.  Exosome Theranostics: Biology and Translational Medicine.

Authors:  Chuanjiang He; Shu Zheng; Yan Luo; Ben Wang
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

8.  Need for Specialized Therapeutic Stem Cells Banks Equipped with Tumor Regression Enzymes and Anti-Tumor Genes.

Authors:  Mujib Ullah
Journal:  J Biomed Allied Res       Date:  2020-03-16

Review 9.  Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.

Authors:  Kaavya Jayaramayya; Iyer Mahalaxmi; Mohana Devi Subramaniam; Neethu Raj; Ahmed Abdal Dayem; Kyung Min Lim; Se Jong Kim; Jong Yub An; Yoonjoo Lee; Yujin Choi; Arthi Raj; Ssang-Goo Cho; Balachandar Vellingiri
Journal:  BMB Rep       Date:  2020-08       Impact factor: 4.778

View more
  6 in total

Review 1.  Different Sourced Extracellular Vesicles and Their Potential Applications in Clinical Treatments.

Authors:  Leila Bahmani; Mujib Ullah
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

2.  Artificial intelligence and guidance of medicine in the bubble.

Authors:  Asma Akbar; Nagavalli Pillalamarri; Sriya Jonnakuti; Mujib Ullah
Journal:  Cell Biosci       Date:  2021-06-09       Impact factor: 7.133

Review 3.  Cytidine deamination-induced perpetual immunity to SAR-CoV-2 infection is a potential new therapeutic target.

Authors:  Asad Ullah; Neelam Mabood; Muhammad Maqbool; Luqman Khan; Mujib Ullah
Journal:  Int J Med Sci       Date:  2021-10-15       Impact factor: 3.738

Review 4.  Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy.

Authors:  María Cecilia Sanmartin; Francisco Raúl Borzone; María Belén Giorello; Gustavo Yannarelli; Norma Alejandra Chasseing
Journal:  Front Bioeng Biotechnol       Date:  2022-04-14

Review 5.  Exosomes: Insights and therapeutic applications in cancer.

Authors:  Anita Raj Panigrahi; Lankalapalli Srinivas; Jagadeesh Panda
Journal:  Transl Oncol       Date:  2022-05-09       Impact factor: 4.803

Review 6.  Methodologies to Isolate and Purify Clinical Grade Extracellular Vesicles for Medical Applications.

Authors:  Asma Akbar; Farzaneh Malekian; Neda Baghban; Sai Priyanka Kodam; Mujib Ullah
Journal:  Cells       Date:  2022-01-06       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.